Clinigen Group Plc (CLINC)

London
925.00
0.00(0.00%)
  • Volume:
    0
  • Bid/Ask:
    922.00/925.50
  • Day's Range:
    924.00 - 925.00

CLINC Overview

Prev. Close
924
Day's Range
924-925
Revenue
807.5M
Open
924
52 wk Range
541.5-948.05
EPS
0.21
Volume
0
Market Cap
1.23B
Dividend (Yield)
0.05
(0.82%)
Average Volume (3m)
1,519,907
P/E Ratio
44.84
Beta
1.75
1-Year Change
12.12%
Shares Outstanding
133,361,298
Next Earnings Date
13 Sept 2022
What is your sentiment on Clinigen?
or
Market is currently closed. Voting is open during market hours.

Clinigen Group Plc News

Clinigen Group Plc Company Profile

Clinigen Group Plc Company Profile

Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. It operates through Services and Products divisions. The company provides a set of niche and high value services to pharma and biotech clients prior to product launch. It also provides access to critical medicines around the world for patients with unmet needs. In addition, the company provides a portfolio of specialist medicines to service the needs of healthcare professionals and their patients in both licensed and unlicensed markets. Further, it offers Nortriptyline Colonis for the treatment of depressive disorder; Metformin Colonis for the treatment of type 2 diabetes mellitus; Magnesium Chewable Tablets, an oral magnesium supplements for the treatment of patients with chronic magnesium loss; Iloprost, a concentrate for solution for infusion; Glycopyrronium Bromide, an oral solution for the treatment of severe sialorrhoea; Acetylcysteine, an oral solution for the treatment of respiratory disorders associated with thick, viscous, and mucus hypersecretion; Cardioxane that protects the heart against the cardiotoxic effects of anthracyclines; Ethyol, which protect against the harmful effects of chemotherapy medications and radiation treatment; Proleukin for the treatment of kidney cancer; Imukin that is used in chronic granulomatous disease; Totect, a dexrazoxane product; Foscavir, an anti-virals that work by stopping viruses from multiplying in number; and Savene, which is indicated in adults for the treatment of anthracycline extravasation. The company was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom. As of April 4, 2022, Clinigen Group plc was taken private.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyBuyStrong BuyStrong Buy
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
  • People have had a go at this stock to “release value” when it has been £8 -£10. On that basis, from here, id the bid is successful, there 40 - 70% upside in the next week or so…
    0
    • And here comes ANOTHER bid for Clinigen. The problem is - nobody knows how to value it…
      0
      • An ideal target for takeover
        0